Pathobiology of the sentinel node

Current Opinion in Oncology

Volumn 20, Issue 2, 2008, Pages 190-195

  Cochran, Alistair J ^a,b   Ohsie, Steven J ^a   Binder, Scott W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Completion lymph node dissection; Immune suppression; Lymphatic mapping; Melanoma; Sentinel node

Indexed keywords

BLUE NEVUS; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; LYMPHADENECTOMY; MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENTINEL LYMPH NODE BIOPSY;

HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 39849083317     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f46d70     Document Type: Review

References (55)

1. Cochran AJ, Roberts A, Wen DR, et al. Update on lymphatic mapping and sentinel node biopsy in the management of patients with melanocytic tumours. Pathology 2004; 36:478-484.
2. Gimotty PA, Botbyl J, Soong S, et al. A population-based validation of the AJCC melanoma staging system. J Clin Oncol 2005; 23:8065-8075.
3. Balch CM, Cascinelli N. Sentinel node biopsy in melanoma. N Engl J Med 2006; 355:1370-1371. This provides an excellent commentary on recent large studies demonstrating the role of sentinel node biopsy in the evaluation of cutaneous melanoma.
4. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-399.
5. Davids V, Kidson SH, Hanekom GS. Melanoma patient staging: histopathological versus molecular evaluation of the sentinel node. Melanoma Res 2003; 13:313-324.
6. Kuo CT, Hoon DS, Takeuchi H, et al. Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol 2003; 21:3566-3572.
7. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multiinstitutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006; 24:2849-2857. A large prospective multicenter study (1446 patients) with histologically negative sentinel nodes used RT-PCR for four different melanoma markers (tyrosinase, MART1, MAGE3, GP-100). There was no difference in disease free or overall survival between RT-PCR positive and RT-PCR negative sentinel lymph nodes. There was a significant decrease in disease free but not overall survival in patients with more than one positive marker by RT-PCR in peripheral blood.
8. Gradilone A, Ribuffo D, Silvestri I, et al. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance. Ann Surg Oncol 2004; 11:983-987.
9. Bostick PJ, Morton DL, Turner RR, et al. Prognostic significance of occult metastasis detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17:3238-3244.
10. Kammula US, Ghossein R, Bhattacharya S, Coit DG. Serial follow-up and the prognostic significance of reverse-transcriptase-polymerase chain reaction-staged sentinel lymph nodes from melanoma patients. J Clin Oncol 2004; 22:3989-3996.
11. Mangas C, Hilari JM, Paradelo C, et al. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase- polymerase chain reaction for tyrosinase in melanoma patients. Ann Surg Oncol 2006; 13:910-918. A study of 180 patients showed that while 86 of these patients had RT-PCR positivity for tyrosinase in histologically negative sentinel lymph nodes, there was no difference in disease free or overall survival.
12. Tatlidil C, Parkhill WS, Giacomantonio CA, et al. Detection of tyrosinase mRNA in the sentinel lymph node of melanoma patients is not a predictor of short-term disease recurrence. Mod Pathol 2007; 20:427-434. A study of 139 patients demonstrated that while the presence of a histologically positive sentinel lymph node decreases overall and disease free survival, the presence of an RT-PCR positive (tyrosinase) sentinel lymph node does not affect disease free or overall survival.
13. Romanini A, Manca G, Pellegrino D, et al. Molecular staging of the sentinel lymph node in melanoma patients: correlation with clinical outcome. Ann Oncol 2005; 16:1832-1840.
14. Denninghoff VC, Kahn AG, Falco J, et al. Sentinel lymph node: detection of micrometastases of melanoma in a molecular study. Mol Diagn 2004; 8:253-258.
15. Takeuchi H, Morton DL, Kuo C, et al. Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004; 22:2671-2680.
16. Ulrich J, Bonnekoh B, Bockelmann R, et al. Prognostic significance of detecting micrometastases by tyrosinase RT/PCR in sentinel lymph node biopsies: lessons from 322 consecutive melanoma patients. Eur J Cancer 2004; 40:2812-2819.
17. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307-1317. This large prospective trial (1269 patients) demonstrated the efficacy of sentinel node biopsy over observation in patients with intermediate thickness (1.2-3.5 mm) cutaneous melanoma. There was a significant decrease in the 5-year survival rate in patients with a positive sentinel lymph node. Furthermore, patients with nodal metastasis had an increased 5-year survival rate when treated by sentinel node biopsy followed by immediate CLND rather than observation and delayed lymph node dissection.
18. Morton DL, Cochran AJ, Thompson JF. Sentinel-node biopsy in melanoma: author reply. N Engl J Med 2007; 356:419-420. This is a response to questions raised by the previous study [17••].
19. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
20. Haigh PI, Lucci A, Turner RR, et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 2001; 92:535-541.
21. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological Stage I malignant melanoma: An immunohistological study. Amer J Surg Pathol 1988; 12:612-618.
22. Morton DL, Cochran AJ. Vital dye mapping to identify regional lymph node metastases seeded from a primary cutaneous melanoma. Perspect Gen Surg 1993; 4:1-9.
23. Cochran AJ. Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes. Am J Surg Pathol 1999; 23:1169-1172.
24. Cochran AJ. The pathologist's role in sentinel lymph node evaluation. Semin Nucl Med 2000; 30:11-17.
25. Cochran AJ. Sentinel lymph node pathology. Progress in Pathology 2001; 5:45-56.
26. Cochran AJ, Wen DR, Herschman HR, et al. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982; 30:295-297.
27. Cochran AJ, Bailly C, Paul E, et al. Melanocytic tumors: a guide to diagnosis. Philadelphia and New York: Lippincott-Raven; 1997.
28. Cochran AJ, Pihl E, Wen D-R, et al. Zoned immune suppression of lymph nodes draining malignant melanoma: histologic and immunohistologic studies. J Natl Cancer Inst 1987; 78:399-405.
29. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol (in press).
30. Starz H, De Donno A, Balda BR. The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 2001; 8:48S-51S.
31. Brady M, Thayer D. Review of published experience. In: Cody III HS, editor. Sentinel lymph node biopsy. New York: Martin Dunitz; 2002. pp. 161-173.
32. Morton DL, Hoon DSB, Cochran AJ, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003; 238:538-549.
33. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 2004; 17:747-755.
34. Spanknebel K, Coit DG, Bieligk SC, et al. Characterization of micrometastatic disease in melanoma sentinel lymph nodes by enhanced pathology: recommendations for standardizing pathologic analysis. Am J Surg Pathol 2005; 29:305-317.
35. Cook MG, Green MA, Anderson B. The development of optimal pathologic assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200:314-319.
36. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol 2004; 11:162S-168S.
37. Dewar DJ, Newell B, Green AP, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol 2004; 22:3345-3349.
38. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 2003; 10:27-31.
39. Roka F, Mastan P, Binder M, et al. Prediction of nonsentinel node status and outcome in sentinel node-positive melanoma patients. Eur J Surg Oncol 2007; 12 Mar [Epub ahead of print] This study of 504 patients demonstrated that none of the current histologic parameters or algorithms evaluating positive sentinel lymph nodes can reliably predict the presence or absence of nonsentinel nodal metastasis. The authors conclude that CLND is still recommended for all patients with positive sentinel lymph nodes.
40. van Akkooi ACJ, de Wilt JHW, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17:1578-1585. A study of 74 patients with positive sentinel nodes showed that nodal metastasis is statistically related only to sentinel node tumor burden. Furthermore, there was no nodal metastasis and no decrease in survival in patients with sentinel nodal micrometastasis under 0.1 mm. The authors suggest that these patients may not need CLNDs. We, however, disagree with this conclusion.
41. Sabel MS, Griffith K, Sondak VK, et al. Predictors of a nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 2005; 201:37-47.
42. Satzger I, Volker B, Al Ghazal M, et al. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients. Histopathology 2007; 50:764-772. An analysis of 169 positive sentinel nodes showed that increased tumor burden over 2 mm, infiltration of the capsule, and largest tumor deposit over 30 cells all correlate with a poor prognosis.
43. Page AJ, Carlson GW, Delman KA, et al. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg 2007; 73:674-679. This retrospective review of 70 patients with positive sentinel lymph nodes did not show any histologic feature of the sentinel node which was predictive of non-sentinel nodal metastasis.
44. Scoyler RA, Li LXL, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 2004; 122:532-539.
45. Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanoma. Am J Surg Pathol 1996; 20:834-840.
46. McCarthy SW, Palmer AA, Bale PM, Hirst E. Naevus cells in lymph nodes. Pathology 1974; 6:351-358.
47. Fischer B, Fischer ER. Studies concerning the regional lymph node. II. Maintenance of immunity. Cancer 1971; 27:1001-1004.
48. Cochran AJ, Wen DR, Farzad Z, et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res 1989; 9:859-864.
49. Cochran AJ, Morton Dl, Stern S, et al. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol 2001; 14:604-608.
50. Lana AM, Wen DR, Cochran AJ. The morphology, immunophenotype, and distribution of paracortical dendritic leukocytes in lymph nodes regional to cutaneous melanoma. Melanoma Res 2001; 11:401-410.
51. Matsuura K, Yamaguchi Y, Ueno H, et al. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer 2006; 106:1227-1326. This was a prospective study of 70 sentinel nodes in patients with breast cancer. Flow cytometry showed that positive sentinel nodes had decreased numbers of CD40, CD80, CD86, and HLA-DR positive cells. By RT-PCR, the positive nodes had higher expression of CD83, IL-12, IFN-γ, IL-10, and Foxp3. These findings suggest that a tumor-modulated decrease in immune response may predispose to nodal metastasis in breast cancer.
52. Vuylsteke RJ, Molenkamp BG, Gietema HA, et al. Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res 2004; 64:8456-8460.
53. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Review Immunol 2004; 4:941-952.
54. Cochran AJ, Huang RR, Lee J, et al. Tumor-induced immune modulation of sentinel lymph nodes. Nat Review Immunol 2006; 6:659-670. This provides analysis of the theory that melanoma immunologically inhibits production of tumor-specific cytotoxic T-cells, thereby predisposing lymph nodes to metastasis. This paper also explores the use of GM-CSF as an agent to reverse this immune modulation.
55. Lee JH, Torisu-Itakara H, Cochran AJ, et al. Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005; 11:107-112.